200 related articles for article (PubMed ID: 31793219)
21. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.
Campanilho-Marques R; Deakin CT; Simou S; Papadopoulou C; Wedderburn LR; Pilkington CA;
Arthritis Res Ther; 2020 Apr; 22(1):79. PubMed ID: 32293539
[TBL] [Abstract][Full Text] [Related]
22. Twelve years experience of juvenile dermatomyositis in North India.
Singh S; Bansal A
Rheumatol Int; 2006 Apr; 26(6):510-5. PubMed ID: 16163542
[TBL] [Abstract][Full Text] [Related]
23. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.
Soponkanaporn S; Deakin CT; Schutz PW; Marshall LR; Yasin SA; Johnson CM; Sag E; Tansley SL; McHugh NJ; Wedderburn LR; Jacques TS
Neuropathol Appl Neurobiol; 2019 Jun; 45(4):410-420. PubMed ID: 29770465
[TBL] [Abstract][Full Text] [Related]
24. Disease patterns of juvenile dermatomyositis from Western India.
Chickermane PR; Mankad D; Khubchandani RP
Indian Pediatr; 2013 Oct; 50(10):961-3. PubMed ID: 23798628
[TBL] [Abstract][Full Text] [Related]
25. Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study.
Faller G; Mistry BJ; Tikly M
Pediatr Rheumatol Online J; 2014 Jan; 12():2. PubMed ID: 24397895
[TBL] [Abstract][Full Text] [Related]
26. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study.
Sanner H; Kirkhus E; Merckoll E; Tollisen A; Røisland M; Lie BA; Taraldsrud E; Gran JT; Flatø B
Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1103-11. PubMed ID: 20506141
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study.
Okong'o LO; Esser M; Wilmshurst J; Scott C
Pediatr Rheumatol Online J; 2016 Nov; 14(1):60. PubMed ID: 27835954
[TBL] [Abstract][Full Text] [Related]
28. Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis.
Quiñones R; Morgan GA; Amoruso M; Field R; Huang CC; Pachman LM
Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1697-701. PubMed ID: 23666925
[TBL] [Abstract][Full Text] [Related]
29. [Juvenile dermatomyositis: A series of 22 cases].
Moegle C; Lipsker D
Ann Dermatol Venereol; 2020 Sep; 147(8-9):494-503. PubMed ID: 32532518
[TBL] [Abstract][Full Text] [Related]
30. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children.
Pachman LM; Hayford JR; Chung A; Daugherty CA; Pallansch MA; Fink CW; Gewanter HL; Jerath R; Lang BA; Sinacore J; Szer IS; Dyer AR; Hochberg MC
J Rheumatol; 1998 Jun; 25(6):1198-204. PubMed ID: 9632086
[TBL] [Abstract][Full Text] [Related]
31. Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review.
Gonçalves Júnior J; Shinjo SK
Curr Rheumatol Rep; 2024 Feb; 26(2):53-68. PubMed ID: 38060107
[TBL] [Abstract][Full Text] [Related]
32. Juvenile dermatomyositis: association between nail fold capillary end row loop- area under the curve- and disease damage indicators.
Khojah A; Morgan G; Klein-Gitelman MS; Pachman LM
Pediatr Rheumatol Online J; 2023 Nov; 21(1):137. PubMed ID: 37957619
[TBL] [Abstract][Full Text] [Related]
33. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity.
Schwartz T; Sanner H; Gjesdal O; Flatø B; Sjaastad I
Ann Rheum Dis; 2014 Oct; 73(10):1805-10. PubMed ID: 23881732
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients.
Mathiesen PR; Zak M; Herlin T; Nielsen SM
Clin Exp Rheumatol; 2010; 28(5):782-9. PubMed ID: 21029565
[TBL] [Abstract][Full Text] [Related]
35. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases.
Sato JO; Sallum AM; Ferriani VP; Marini R; Sacchetti SB; Okuda EM; Carvalho JF; Pereira RM; Len CA; Terreri MT; Lotufo SA; Romanelli PR; Ramos VC; Hilario MO; Silva CA; Corrente JE; Saad-Magalhães C;
Clin Exp Rheumatol; 2009; 27(6):1031-8. PubMed ID: 20149327
[TBL] [Abstract][Full Text] [Related]
36. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.
Huber AM; Lang B; LeBlanc CM; Birdi N; Bolaria RK; Malleson P; MacNeil I; Momy JA; Avery G; Feldman BM
Arthritis Rheum; 2000 Mar; 43(3):541-9. PubMed ID: 10728746
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the biomarkers related to the clinical course and outcomes of juvenile dermatomyositis.
Lin TW; Hu YC; Chiang BL
J Microbiol Immunol Infect; 2023 Apr; 56(2):416-423. PubMed ID: 36572597
[TBL] [Abstract][Full Text] [Related]
38. Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage.
Sanner H; Schwartz T; Flatø B; Vistnes M; Christensen G; Sjaastad I
PLoS One; 2014; 9(3):e92171. PubMed ID: 24647150
[TBL] [Abstract][Full Text] [Related]
39. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.
McCann LJ; Juggins AD; Maillard SM; Wedderburn LR; Davidson JE; Murray KJ; Pilkington CA;
Rheumatology (Oxford); 2006 Oct; 45(10):1255-60. PubMed ID: 16567354
[TBL] [Abstract][Full Text] [Related]
40. Juvenile Dermatomyositis in Afro-Caribbean children: a cohort study in the French West Indies.
Felix A; Delion F; Louis-Sidney F; Osei L; Armougon A; Bellance R; Dramé M; Deligny C; Suzon B; Hatchuel Y
Pediatr Rheumatol Online J; 2023 Oct; 21(1):113. PubMed ID: 37805487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
